1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CCR

CCR

CC chemokine receptor

CCR (Chemokine receptors) are cytokine receptors found on the surface of certain cells that interact with a type of cytokine called achemokine. There have been 19 distinct chemokine receptors described in mammals. Each has a 7-transmembrane (7TM) structure and couples to G-protein for signal transduction within a cell, making them members of a large protein family of G protein-coupled receptors. Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca2+) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism. Chemokine receptors are divided into different families, CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct subfamilies of chemokines they bind. Specific chemokine receptors provide the portals for HIV to get into cells, and others contribute to inflammatory diseases and cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990592
    GSK-3050002 (E-6071)
    GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    GSK-3050002 (E-6071)
  • HY-168330
    CCR8 agonist 1
    Agonist
    CCR8 agonist 1 (Compound 2) is a CCR8 agonist that can be used for research on autoimmune diseases.
    CCR8 agonist 1
  • HY-13004S
    Maraviroc-d6
    Antagonist
    Maraviroc-d6 (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV[1][2].
    Maraviroc-d<sub>6</sub>
  • HY-P990653
    R707
    Inhibitor
    R707 is a human antibody expressed in CHO cells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    R707
  • HY-103360A
    cis-J-113863
    Antagonist
    cis-J-113863 is a competitive chemokine receptor 1 (CCR1) antagonist, with IC50 values of 0.9 and 5.8 nM for human and mouse CCR1 receptors, respectively.
    cis-J-113863
  • HY-P99474
    Bertilimumab
    Inhibitor
    Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research.
    Bertilimumab
  • HY-162505
    SQA1
    Antagonist
    SQA1, a squaramide (SQA) derivative, is a CCR6 antagonist with a Kd of 250 nM. SQA1 is also a CXCR2 inhibitor. The intracellular pocket occupied by SQA1 overlaps with the G protein binding site and stabilizes the closed conformation of the intracellular pocket.
    SQA1
  • HY-123902
    Ophiobolin C
    Inhibitor
    Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells. Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells.
    Ophiobolin C
  • HY-14231
    CCR5 antagonist 5
    Antagonist
    CCR5 antagonist 5 (compound example 11) is a CCR5 antagonist. CCR5 antagonist 5 has the potential to study inflammation and immunity and viral (such as HIV) infection.
    CCR5 antagonist 5
  • HY-103360B
    trans-J-113863
    Antagonist
    trans-J-113863 is a potent chemokine CCR1 and CCR3 receptor antagonist, and inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC50 of 9.57 and 93.8 nM,respectively.
    trans-J-113863
  • HY-160647
    CCR8 antagonist 3
    Antagonist
    CCR8 antagonist 3 (compound 2) is a CCR8 antagonist with an IC50 value of 0.062 µM. CCR8 antagonist 3 shows human microsomal stability.
    CCR8 antagonist 3
  • HY-P4191A
    Met-RANTES (human) (acetate)
    Antagonist 99.62%
    Met-RANTES (human) acetate is the acetate form of Met-RANTES (human) (HY-P4191). Met-RANTES (human) acetate is the antagonist for CCR1 and CCR5. Met-RANTES (human) acetate inhibits chemokines human MIP-1α and MIP-1β with IC50 of 5 and 2 nM. Met-RANTES (human) acetate reduces bone destruction and ameliorates rats adjuvant-induced arthritis (AIA).
    Met-RANTES (human) (acetate)
  • HY-124474
    Procurcumenol
    Procurcumenol, a natural compound that can be isolated from Curcuma zedoaria Rhizomes, possesses neuroprotective and antioxidant activity.
    Procurcumenol
  • HY-12944
    GSK163929
    Antagonist
    GSK163929 (compound 122) is an orally active, anti-HIV CCR5 antagonist with low inhibitory potency against hEGR. GSK163929 had no adverse effects in rats at 2000 mg/kg/day (i.v., 7 d) and in dogs at 250 mg/kg/day (i.v., 7 d).
    GSK163929
  • HY-111037
    BMS-457
    Antagonist
    BMS-457 is a potent and selective CCR1 antagonist. BMS-457 can be used in the study of rheumatoid arthritis.
    BMS-457
  • HY-160658
    AZ760
    Antagonist
    AZ760 is a CCR8 antagonist. AZ760 shows excellent potency, good lipophilicity and high free fraction in blood. AZ760 exhibits unacceptable hERG inhibition.
    AZ760
  • HY-123270
    RP23618
    Antagonist
    RP23618 is a non peptidic RANTES antagonist with the IC50 of 3 μM. RP23618 inhibit RANTES-induced chemotaxis of THP-1 cells.
    RP23618
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.